Candel Therapeutics, Inc. ( (CADL) ) has released its Q1 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, is focused on developing multimodal biological immunotherapies to combat cancer, with a particular emphasis on solid tumors.
In its first quarter of 2025, Candel Therapeutics reported significant progress in its clinical trials and financial performance. The company highlighted positive results from its phase 3 clinical trial of CAN-2409 for prostate cancer, along with promising data from trials in non-small cell lung cancer (NSCLC) and pancreatic cancer.
Key financial metrics showed a net income of $7.4 million for the first quarter of 2025, a substantial improvement from a net loss of $8.2 million in the same period of 2024. This turnaround was largely attributed to changes in the fair value of the company’s warrant liability. Additionally, Candel’s cash position stood at $92.2 million, expected to sustain operations into early 2027.
Strategically, Candel is preparing for a Biologics License Application submission for CAN-2409 in prostate cancer by the end of 2026, while also advancing its pipeline in other cancer types. The company has entered a strategic collaboration with IDEA Pharma to enhance commercialization efforts for CAN-2409.
Looking ahead, Candel Therapeutics remains focused on advancing its clinical programs and preparing for potential commercialization, with management expressing optimism about the transformative potential of their therapies in addressing unmet medical needs in oncology.